Investors continued to fund health‑focused companies: Grow Therapy closed a $150 million Series D to expand employer and health‑system partnerships, while sector trackers flagged the largest biotech funding rounds in February led by Vaxcyte, Generate Biomedicines and Immunic. The activity underscores sustained venture interest in digital behavioral health and platform biotech despite wider market caution. Large growth rounds and strategic financings are being directed toward companies that can show near‑term commercial traction or platform scalability. Observers say capital allocation is shifting toward deals that demonstrate clear clinical and revenue pathways, with consolidated investor syndicates backing later‑stage expansion.